Tazemetostat + Nivolumab + Ipilimumab

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Teratoid Rhabdoid Tumor

Conditions

Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma

Trial Timeline

Aug 10, 2023 → Feb 1, 2029

NCT ID

NCT05407441

About Tazemetostat + Nivolumab + Ipilimumab

Tazemetostat + Nivolumab + Ipilimumab is a phase 1/2 stage product being developed by Bristol Myers Squibb for Atypical Teratoid Rhabdoid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05407441. Target conditions include Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors.

What happened to similar drugs?

1 of 8 similar drugs in Atypical Teratoid Rhabdoid Tumor were approved

Approved (1) Terminated (0) Active (7)

🔄CrovalimabChugai PharmaceuticalPhase 3

✅DuloxetineEli LillyApproved

🔄Teriparatide 20 mcgEli LillyPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05407441	Phase 1/2	Recruiting	Aug 10, 2023	Feb 1, 2029	Atypical Teratoid Rhabdoid Tumor

Competing Products

18 competing products in Atypical Teratoid Rhabdoid Tumor

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Duloxetine	Eli Lilly	Approved	43
Teriparatide 20 mcg	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Pre-clinical	26
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Iptacopan	Novartis	Phase 3	47
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	42
CCX168	Amgen	Phase 2	27
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	24
Axatilimab + Azacitidine	Incyte	Phase 1/2	36
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	32
Apatinib Mesylate	Brain Biotech	Pre-clinical	23
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	19